SAB Biotherapeutics moves to bolster board
SAB Biotherapeutics, a clinical-stage biopharmaceutical development company, announced that it had appointed Thorkil Kastberg Christensen to its Board of Directors. The company focuses on developing antibody therapeutics using an immunotherapy platform.
Christensen joins the board of SAB having spent the majority of his career at Novo Nordisk. He performed the role of CFO at Novo A/S, the holding company of the Novo Group and the asset management company of the Novo Nordisk Foundation. He was in the role for 12 years, managing assets estimated to be worth $40 billion. He left the role in 2015 but now acts as an advisor for Novo A/S, as well as Strategic Design Group and Sonion A/S.
“The possibilities for using human antibodies, and polyclonals in particular, for the benefit of mankind are endless and in many areas there are great commercial potentials as well,” commented Christensen on his appointment. “I look forward to working closer with the colleagues at SAB in striving to realize some of these potentials.”
“Mr. Christensen has been a trusted advisor and asset to SAB as we have advanced our technology and expanded collaborations within the U.S. and globally,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics. “His experience with financing, technology deployment and his network with leading public health, biotech and Pharma organizations will be valuable to the board as we continue to build our footprint and portfolio”.